Opinion
Video
Long-term Safety of JAK Inhibitors in Atopic Dermatitis
Author(s):
Key Takeaways
- Long-term upadacitinib data reveal sustained efficacy and safety, offering insights beyond short-term studies for atopic dermatitis management.
- Comparisons with other JAK inhibitors highlight differences in long-term outcomes, influencing clinical decision-making.
EP: 1.Heterogenous Presentation of Atopic Dermatitis
EP: 2.Burden of Atopic Dermatitis and its Impact on Patient’s Quality of Life
EP: 3.Patient’s Goals and Atopic Dermatitis Treatment Selection
EP: 4.Talking to Patients about Atopic Dermatitis Treatment Response
EP: 5.Use of PRO in Atopic Dermatitis Clinical Practice
EP: 6.Incorporating Patient Preferences in the Treatment of Atopic Dermatitis
EP: 7.Changing Standard of Care in Atopic Dermatitis
EP: 8.Unmet Needs and Gaps in AD
EP: 9.Looking Beyond Type 2 Inflammation in Atopic Dermatitis
EP: 10.JAK Inhibitors in Atopic Dermatitis
EP: 11.Safety Profile of JAK Inhibitors and their Use in Atopic Dermatitis
EP: 12.Monitoring Schedule for JAK Inhibitors in Atopic Dermatitis
EP: 13.Data from LEVEL UP Trial with Upadacitnib in Atopic Dermatitis
Now Viewing
EP: 14.Long-term Safety of JAK Inhibitors in Atopic Dermatitis
EP: 15.Use of JAK Inhibitors and Systemic Treatments for Atopic Dermatitis
EP: 16.Treatment of Bio-Naïve Patients or Those Progressing on Topical or Biologic Atopic Dermatitis Therapy
EP: 17.Emerging Treatments for Atopic Dermatitis
Video content above is prompted by the following:
- Are there any learnings from long-term upadacitinib data that were not seen in short-term data?
- What about short vs long-term data with other JAKi?
- How do they impact your use of JAKi for atopic dermatitis?
Related Videos
Related Content
